What does a 12-month outcome actually look like after combining surgery with stem cell injections for a patella cartilage fissure?
A patellar cartilage fissure is a crack or split in the articular cartilage covering the underside of the kneecap (patella). Cartilage doesn't bleed. It has no nerve supply of its own. And it receives nutrients only through diffusion from the surrounding joint fluid — which means it heals very poorly on its own.
Surgery for patellar cartilage fissures typically involves one of several approaches: debridement (smoothing the damaged surface), microfracture (creating small perforations in the subchondral bone to stimulate a healing response), or in more complex cases, autologous chondrocyte implantation (ACI). Each has a defined role — and each has limitations.
Clinical trial data on intra-articular MSC therapy for knee cartilage pathology — including patellar lesions — has grown substantially over the past decade. The evidence base is heterogeneous (different cell sources, doses, timing, and patient profiles make direct comparison difficult), but several consistent signals have emerged.
Honesty here matters more than optimism. Several questions remain genuinely open in the literature — and patients deserve to know what those are before making a decision.
Candidacy for the combined surgery-plus-MSC approach is determined by clinical assessment — not by symptom severity alone. Our medical team reviews imaging (weight-bearing X-ray and MRI with cartilage-specific sequences), patient history, prior treatments, BMI, alignment, and activity goals before any recommendation is made.
Before any protocol is recommended, our team reviews your full orthopaedic history: imaging, surgical reports if applicable, medication list, and your rehabilitation history. We may request updated MRI imaging if existing scans are more than six months old. This is not a formality — candidacy is genuinely assessed, not assumed.
The treatment plan specifies cell source, dose, administration route (intra-articular injection directly into the knee joint), timing relative to surgery if applicable, and follow-up schedule. For patients combining MSC injection with a planned surgical procedure, coordination with the operating surgeon is part of the planning process.
Intra-articular MSC injection for a knee cartilage indication is typically an outpatient procedure. The injection takes 30–60 minutes including preparation. Image guidance (ultrasound) is used to ensure accurate placement. Most patients experience minimal discomfort during the procedure and can mobilise the same day, with activity restrictions in the first 48–72 hours.
Follow-up is structured around clinical outcome measures and, where indicated, repeat imaging. Patients returning home after treatment receive a written follow-up protocol to share with their local orthopaedist or physiotherapist. Our coordination team remains available for questions throughout the recovery period.
We use umbilical cord-derived mesenchymal stem cells (UC-MSCs) — allogeneic cells sourced from ethically donated umbilical cord tissue. These are processed under GMP-aligned conditions and cryopreserved at -196°C until use.
Patients who respond well to the combined approach typically describe their 12-month status in functional terms: they're walking further without pain, returning to lower-impact activities they had given up, and using fewer or no anti-inflammatory medications. Some describe near-normal knee function. Others describe meaningful but partial improvement — reduced pain frequency, better tolerance of stairs, but continued limitations during sustained activity.
Intra-articular MSC injection has a well-characterised short-term safety profile across published trials. The most commonly reported adverse effects are transient post-injection joint swelling and mild discomfort, typically resolving within 48–72 hours. These are procedural side effects rather than cell-related toxicity.
This is one of the most common questions international patients ask — and it deserves a direct answer.
Most international patients planning intra-articular MSC therapy as a standalone outpatient procedure require a stay of 3–5 days in Istanbul. This allows time for pre-treatment clinical review, the procedure itself, and a post-procedure assessment before travel.
Yes — and it's the right timeframe to look at. Cartilage biology is slow. The healing processes MSC therapy supports — chondrogenic differentiation, inflammation resolution, extracellular matrix remodelling — operate over months, not weeks. Most published trials use 12 months as their primary endpoint because that's when the clearest picture of treatment response emerges.
Most patients describe the injection as similar in discomfort to a standard knee aspiration — a sharp pressure sensation rather than sharp pain, lasting seconds. Local anaesthetic is applied beforehand. Post-procedure discomfort, including joint swelling and mild aching, is common for 24–72 hours. Severe or worsening pain after this window should be reported promptly to the treating physician.
Yes, in appropriate cases. Intra-articular MSC injection can be performed as a standalone procedure for patients with grade II–III fissures who are not yet surgical candidates, or who prefer a conservative approach before committing to surgery. The evidence base for standalone MSC injection in focal cartilage lesions is growing, though the combined surgical-plus-MSC approach has the stronger current evidence base in the published trial literature. Your clinical assessment determines which pathway is appropriate.
MRI at 12 months may show improved cartilage signal intensity and better defect fill — both of which are associated with better clinical outcomes in trial populations. However, not all MRI improvement translates directly to equivalent symptom relief, and not all clinical improvement is visible on standard MRI sequences. Cartilage-specific MRI protocols (T2 mapping, dGEMRIC) offer more sensitivity but are not universally available. Imaging is one data point — not the whole picture.
Most current protocols for patellar cartilage fissures involve one to two intra-articular MSC injections — either a single injection at the time of or shortly after surgery, or a primary injection followed by a booster at three to six months in patients showing partial response. Multi-injection protocols are not yet standardised, and the decision to repeat treatment is made on the basis of clinical response at follow-up, not as a fixed protocol element.
In most countries, intra-articular MSC therapy for cartilage indications is not covered by state or private health insurance because it has not yet completed the full regulatory approval pathway for reimbursement in those jurisdictions. Treatment in Istanbul is self-funded. Cost depends on protocol complexity, number of sessions, and clinical pathway. We provide transparent cost breakdowns at the assessment stage — no undisclosed fees.
If your cartilage fissure has progressed to Grade IV (bone-on-bone), if there is significant malalignment requiring corrective osteotomy, if there is active joint infection, or if you have advanced patellofemoral osteoarthritis with severe functional loss — these are situations where established surgical and orthopaedic care should be the primary pathway. MSC therapy may still have a supporting role in some of these scenarios, but that determination requires orthopaedic specialist review, not regenerative medicine alone. Never delay indicated surgery in the hope that biological therapy will substitute for it.
A patella cartilage fissure is a frustrating injury — structurally significant, slow to heal, and often inadequately addressed by conservative measures alone. If you are 12 months post-surgery and questioning whether more can be done, or if you are pre-surgery and wondering whether a regenerative approach could be integrated into your care plan, the first step is a medical assessment — not a sales call.
12-Month Update: Surgery + Stem Cell Injections for Patella Cartilage Fissure